PET Imaging with [18F]AlF-FAPI-74 and Hyoscine Butylbromide in Patients Suspected of Endometriosis

2 1 1 1

What is this study about?

endometriosis is a condition in which tissue similar to the lining of the uterus grows outside the uterus, often causing pain and fertility problems. In this study an experimental imaging substance called [18F]AlF-FAPI-74 is injected into a vein and a special whole‑body scan called PET/CT is performed. This scan creates detailed pictures that show areas where the abnormal tissue is active, helping doctors see the disease without surgery.

The purpose of the study is to find out whether this new scan can accurately identify deep or superficial endometriosis compared with the current standard method, which is a small‑incision surgical examination known as laparoscopy. Participants will have the injection and scan, and later will undergo the routine surgical procedure so the two sets of findings can be compared. Additional routine imaging tests such as MRI or ultrasound may also be done if they are already part of the patient’s care.

After the initial scan, participants may have a second scan if they start hormone‑blocking medication (often called a GnRH‑agonist or GnRH‑antagonist) to see how the disease changes. Throughout the study, safety is monitored and any side effects are recorded. The overall aim is to determine if this non‑invasive imaging approach can help doctors diagnose and manage endometriosis more effectively.

1 initial visit and preparation

after joining the study, you will attend an initial visit where basic health information is recorded and the schedule for the imaging procedures is confirmed.

you will be informed that a short medication called buscopan will be given to help reduce movement of the intestines during the scan.

2 administration of background medication

on the day of the scan, a healthcare professional will inject buscopan at a dose of 20 mg (20 milligrams) directly into a vein (intravenous injection).

this single dose is given only once before the imaging test.

3 injection of imaging tracer

immediately after the buscopan injection, you will receive an injection of the tracer [18f]alf-fapi-74 at a dose of 600 MBq (600 megabecquerels) through a vein.

the tracer is a radioactive substance that highlights areas of fibroblast activation protein, which are associated with endometriosis.

4 uptake period

after the tracer is injected, you will wait for a short period to allow the substance to travel through your body and bind to the target tissue.

the exact waiting time is determined by the imaging team and is required for optimal image quality.

5 pet/ct scan

you will then undergo a pet/ct examination, which combines a positron emission tomography (pet) scan and a computed tomography (ct) scan.

the scan creates detailed pictures of the pelvis to show where the tracer has accumulated, indicating possible endometriotic lesions.

6 laparoscopic comparison

within a short time after the pet/ct scan, you will have a routine laparoscopic procedure, which is a minimally invasive surgery used to directly view the pelvic organs.

findings from the laparoscopy are compared with the images from the pet/ct scan to assess the diagnostic performance of the tracer.

7 optional second scan for gnrh medication users

if you start treatment with a gnrh medication (a hormone therapy used for endometriosis), the study may include a second pet/ct scan after the medication has been initiated.

this second scan follows the same steps as the first scan (steps 2–5) and allows comparison of lesion number, tracer uptake, and other measurements before and after the hormone therapy.

Who Can Join the Study?

  • You must give a voluntary written permission (informed consent) to join the study.
  • You must be at least 18 years old when you sign the consent form.
  • You must be a woman who is being evaluated for endometriosis.
  • You must have a planned laparoscopy (a small‑incision surgery used to look inside the abdomen) to investigate suspected endometriosis.
  • For the deep infiltrating endometriosis (DE) group, you need either:
    • A doctor who specializes in endometriosis finds deep nodules during a vaginal exam, or
    • An ultrasound or MRI scan shows areas that look like deep infiltrating endometriosis.
  • For the superficial peritoneal endometriosis (SPE) group, you need either:
    • Symptoms that a specialist thinks are typical of superficial endometriosis, such as painful periods, pain during sex, painful urination, painful bowel movements, unusual bleeding, shoulder pain, lung‑related pain that follows the cycle, fatigue, or difficulty getting pregnant, or
    • An ultrasound or MRI scan shows areas that look like superficial endometriosis.

Who Cannot Join the Study?

  • Had abdominal surgery (an operation on the belly area) within the past year.
  • Is pregnant, breast‑feeding, or could become pregnant and is not using a reliable birth‑control method.
  • Is mentally or legally unable to understand the study or cannot follow all required procedures.
  • Has any health problem that the doctor believes could put your safety at risk or affect the study results.
  • Is taking any medication or treatment that might affect safety or the accuracy of the study.
  • Is currently participating in another trial with an experimental medicine or device that is not compatible with this study.
  • Participated in another research study with a radiation dose greater than 1 mSv (a small measure of radiation) in the last 12 months.
  • Has a known hypersensitivity (allergy) to the imaging agent [18F]AlF‑FAPI‑74 or its ingredients.
  • Has ultrasound or MRI images showing lesions that look like ovarian endometriosis or deep infiltrating endometriosis.
  • Has clinical symptoms that suggest ovarian endometriosis or deep infiltrating endometriosis, as judged by an expert clinician.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Katholieke Universiteit te Leuven Leuven Belgium

Other Sites

No sites found in this category

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not yet recruiting
01.09.2026

Trial locations

Buscopan is a medication that contains hyoscine butylbromide. In this study it is given by injection into a vein. The drug works by relaxing smooth muscles in the gut, which can help reduce cramping and make the abdominal area easier to examine during imaging procedures. It is used in the trial as a background medication to improve comfort and image quality.

[AL[18F]F]FAPI-74 is a special imaging agent that contains a tiny amount of a radioactive material called fluorine‑18. It is injected into a vein before a PET/CT scan. The agent seeks out a protein called fibroblast activation protein, which is often found in endometriosis tissue. By lighting up these areas on the scan, doctors can see where endometriosis lesions are located without needing surgery. This tracer is the main test product being evaluated in the trial.

Investigated Diseases:

endometriosis – Endometriosis is a condition in which tissue that resembles the lining of the uterus grows on organs outside the uterus, such as the ovaries, pelvic lining, or bowel. This tissue continues to respond to the monthly hormonal cycle, swelling and bleeding each month. Over time the repeated bleeding can cause small pockets of blood to collect, leading to scar tissue and adhesions that may pull organs together. The lesions can become deeper and spread, often resulting in increasing pelvic discomfort, painful periods, and pain during intercourse. Symptoms may gradually intensify as more tissue is affected.

Trial ID:
2026-525272-25-00
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A study testing vipoglanstat for women with moderate to severe endometriosis-related pain

    Recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Bulgaria Czechia Hungary Italy Poland Romania
  • Study on Using Fluoroestradiol F-18 PET/CT for Detecting Endometriosis in Patients with Pain

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France